COX-2-dependent and potentially cardioprotective effects of negative inotropic substances released after ischemia

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 4, 2007, Pages

  Birkenmeier, Katrin ^a   Staudt, Alexander ^a,d   Schunck, Wolf Hagen ^b   Janke, Irka ^a   Labitzke, Corina ^a   Prange, Thomas ^a   Trimpert, Christiane ^a   Krieg, Thomas ^a   Landsberger, Martin ^a   Stangl, Verena ^c   Felix, Stephan B ^a,d  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Unversitätsmedizin Greifswald   (Germany)

Author keywords

Cyclooxygenase; Potassium adenosine 5 triphosphate channels

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FURA 2 ACETOXYMETHYL ESTER; GLIBENCLAMIDE; INDOMETACIN; INOTROPIC AGENT; LUMIRACOXIB; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM METABOLISM; CALCIUM TRANSPORT; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INOTROPISM; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL ANALYSIS; WESTERN BLOTTING;

EID: 35348974521     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00074.2007     Document Type: Article

References (49)

1. Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase. J Biol Chem 274: 5038-5046, 1999.
2. TREK in cardiomyocytes. J Biol Chem 275: 39110-39116, 2000.
3. 2 in liver macrophages. Prostaglandins Other Lipid Mediat 79: 93-100, 2005.
4. Bolli R, Shinmura K, Tang X, Kodani E, Xuan Y, Guo Y, Dawn B. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55: 506-519, 2002.
5. Camitta MG, Gabel SA, Chulada P, Bradbury JA, Langenbach R, Zeldin DC. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 104: 2453-2458, 2001.
6. Chen J, Capdevila JH, Zeldin DC, Rosenberg RL. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 55: 288-295, 1999.
7. 2 receptor in cultured interstitial cells of Cajal from murine small intestine. Cell Physiol Biochem 18: 187-198, 2006.
8. 1 osteoblast-like cells. Prostaglandins Leukot Essent Fatty Acids 73: 423-430, 2005.
9. + channel protects the ischemic heart. Am J Physiol Heart Circ Physiol 283: H284-H295, 2002.
10. Dupouy VM, Ferre PJ, Uro-Coste E, Lefebvre HP. Time course of COX-1 and COX-2 expression during ischemia-reperfusion in rat skeletal muscle. J Appl Physiol 100: 233-239, 2006.
11. Esser R, Berry C, Zhengming D, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscana K, Urban L, Dazer J, Zhang X, Zhan S, Marshall PJ. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 144: 538-550, 2005.
12. Faivre JF, Findlay I. Action potential duration and activation of ATP-sensitive potassium current in isolated guinea-pig ventricular myocytes. Biochim Biophys Acta 1029: 167-172, 1990.
13. Felix SB, Stangl V, Frank TM, Harms C, Staudt A, Berndt T, Kastner R, Baumann G. Release of a stable cardiodepressant mediator after myocardial ischemia during reperfusion. Cardiovasc Res 35: 68-79, 1997.
14. Felix SB, Stangl V, Pietsch P, Bramlage P, Staudt A, Bartel S, Krause EG, Borschke JU, Wernecke KD, Isenberg G, Baumann G. Soluble substances released from postischemic reperfused rat hearts reduce calcium transient and contractility by blocking the L-type calcium channel. J Am Coll Cardiol 37: 668-675, 2001.
15. Ferrari R. The role of mitochondria in ischemic heart disease. J Cardiovasc Pharmacol 28: 1-10, 1996.
16. Fornai M, Blandizzi C, Antonioli L, Coluzzi R, Bernardini N, Segnani C, De Ponti F, Del Tacca M. Differential role of cyclooxygenase 1 and 2 isoformes in the modulation of colonic neuromuscular function in experimental inflammation. J Pharmacol Exp Ther 317: 938-945, 2006.
17. Fryer RM, Hsu AK, Gross GJ. Mitochondrial KATP channel opening is important during index ischemia and following myocardial reperfusion in ischemic preconditional rat hearts. J Mol Cell Cardiol 33: 831-834, 2001.
18. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47: 55-59, 1994.
19. Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans 34: 232-237, 2006.
20. + channels in myocardial ischemia. Jpn Heart J 38: 297-315, 1997.
21. Ishikawa T, Morris PL. Interleukin-1beta signals through a c-Jun N-terminal kinase-dependent inducible nitric oxide synthase and nitric oxide production pathway in Sertoli epithelial cells. Endocrinology 147: 5424-5430, 2006.
22. Kishimoto Y, Yashima K, Morisawa T, Shiota G, Kawasaki H, Hasegawa J. Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat. Colon carcinogenesis is induced by azoxymethane. J Gastroenterol 37: 186 -193, 2002.
23. 3 receptors. Am J Physiol Heart Circ Physiol 281: H959-H968, 2001.
24. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271: 927-934, 1994.
25. Lau WM. Effects of potassium channel blockers on the negative inotropic responses induced by cromakalim and pinacidil in guinea pig heart. Pharmacology 45: 9-16, 1992.
26. + channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J Physiol 537: 811-827, 2001.
27. Mobert J, Becker BF. Cyclooxygenase inhibition aggravates ischemia-reperfusion injury in the perfused guinea pig heart: involvement of isoprostanes. J Am Coll Cardiol 3: 1687-1694, 1998.
28. Muller-Ehmsen J, Brixius K, Hoischen S, Schwinger RH. Inotropic and coronary vasodilatory actions of the K-adenosine triphosphate channel modulator nicorandil in human tissue. J Pharmacol Exp Ther 279: 1220-1228, 1996.
29. Nithipatikom K, DiCamelli RF, Kohler S, Gumina RJ, Falck JR, Campbell WB, Gross GJ. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs. Anal Biochem 292: 115-124, 2001.
30. Nithipatikom K, Moore JM, Isbell MA, Falck JR, Gross GJ. Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol 291: H537-H542, 2006.
31. Norvell SM, Ponik SM, Bowen DK, Gerard R, Pavalko FM. Fluid shear stress induction of COX-2 protein and prostaglandin release in cultured MC3T3-E1 osteoblasts does not require intact microfilaments or microtubules. J Appl Physiol 96: 957-966, 2004.
32. Oh PS, Lee SJ, Lim KT. Glycoprotein isolated from Rhus verniciflua stokes inhibits inflammation-related protein and nitric oxide production in LPS-stimulated RAW264.7 cells. Biol Pharm Bull 30: 111-116, 2007.
33. Oshima M, Oshima H, Taketo MM. Hypergravity induces expression of cyclooxygenase-2 in the heart vessels. Biochem Biophys Res Commun 330: 928-933, 2005.
34. Rebsamen MC, Capoccia R, Vallotton MB, Lang U. Role of cyclooxygenase 2, p38 and p42/44 MAPK in the secretion of prostacyclin induced by epidermal growth factor, endothelin-1 and angiotensin II in rat ventricular cardiomyocytes. J Mol Cell Cardiol 35: 81-89, 2003.
35. Rosolowsky M, Falck JR, Willerson JT, Campbell WB. Synthesis of lipoxygenase and epoxygenase products of arachidonic acid by normal and stenosed canine coronary arteries. Circ Res 66: 608-621, 1990.
36. Satoh E, Yanagisawa T, Taira N. Effects of potassium channels blockers on the negative inotropic responses induced by cromakalim and pinacidil guinea pig atrium. Pharmacology 45: 9-16, 1992.
37. Schrör K. Eicosanoids and myocardial ischemia. Basic Res Cardiol 82: 235-243, 1987.
38. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11: 1096-1103, 2005.
39. 3 receptor. Am J Physiol Heart Circ Physiol 288: H2093-H2101, 2005.
40. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Bhatnagar A, Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 97: 10197-10202, 2000.
41. Smith CJ. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95: 13313-13318, 1998.
42. Stangl V, Felix SB, Meyer R, Berndt T, Kastner R, Wernecke KD, Baumann G. Cardiodepressive mediators are released after ischemia from an isolated heart: role of coronary endothelial cells. J Am Coll Cardiol 29: 1390-1396, 1997.
43. Szenczi O, Kemecsei P, Miklos Z, Ligeti L, Snoeckx LH, Van Riel NA, Op den Buijs J, Van der Vusse GJ, Ivancis T. In vivo heat shock preconditioning mitigates calcium overload during ischemia/reperfusion in the isolated, perfused rat heart. Pflügers Arch 449: 518-525, 2005.
44. Tacconelli S, Capone ML, Patrignani P. Clinical pharmacology of novel selective COX-2 inhibitors. Curr Pharm Des 10: 589-601, 2004.
45. Tripp CS, Blomme EA, Chinn KS, Hardy MM, La Celle P, Pentland AP. Epidermal COX-2 induction following ultraviolet irradiation: suggested mechanism for the role of COX-2 inhibition. J Invest Dermatol 121: 853-861, 2003.
46. Uemura Y, Kobayashi M, Nakata H, Kubota T, Saito T, Bandobashi K, Taguchi H. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: roles of cyclooxygenase-2. Oncol Rep 17: 955-961, 2007.
47. ATP channels. Am J Physiol Heart Circ Physiol 280: H2321-H2328, 2001.
48. Wang Y, Kodani E, Wang J, Zhang SX, Takano H, Tang XL, Bolli R. Cardioprotection during final stage of the late phase of ischemic preconditioning is mediated by neuronal NO synthase in concert with cyclooxygenase-2. Circ Res 95: 84-91, 2004.
49. Yanagisawa T, Hashimoto H, Taira N. The negative inotropic effect of nicorandil is independent of cyclic GMP changes: a comparison with pinacidil and cromakalim in canine atrial muscle. Br J Pharmacol 95: 393-398, 1988.